|  |  |
| --- | --- |
|  | Mepolizumab group |
| T0 (n=20) | T1 (n=20) | T6 (n=14) | P Values (T0-T1) | P Values (T0-T6) |
| Functional parameters:* FEV1(%)
* FEV1(ml)
* TIFFENAU index
 | 84.4±26.62558.86±88669.4±12.4 | 87.1±21.52820±960.772.8±10.26 | 90.3±24.42861±96174.9±11 | 0.040.00370.04 | 0.0370.00260.032 |
| Peripheral eosinophilia(cell/mm3 / %) | 915±617 / 11.4±6.5 | 140±83.5 / 1.6±1.2 | 74±61/1±0.8 | <0.0001 | <0.0001 |
| sL-selectin (ng/ml) | 1442±1003 | 630±413 | NA | 0.0012 | NA |
| KL-6 (U/ml) | 332.7±124 | 310.7±107.1 | 334±136 | ns | ns |
| Lymphocytes immunophenotyping:CD45CD3CD4CD8CD19 NKNKT-like  | 19.1±5.481.8±8.547.9±1231.7±147.8±5.29.9±5.812.21±8.7 | 17.9±7.479.5±7.753.5±8.424±88.3±5.713±168.4±8.3 | 18.9±1377±1151±1321±69±8.712±87±4.5 | nsnsns0.03nsns0.02 | nsnsns0.021nsns0.024 |

Tab 1s functional parameters, peripheral eosinophilia, sL-Selectin, KL-6 and lymphocytes immunphenotyping at t0 t1 and t6 for mepolizumab group.